Premium
Clinical outcomes of the entire papilla preservation technique with and without biomaterials in the treatment of isolated intrabony defects: A randomized controlled clinical trial
Author(s) -
Aslan Serhat,
Buduneli Nurcan,
Cortellini Pierpaolo
Publication year - 2020
Publication title -
journal of clinical periodontology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.456
H-Index - 151
eISSN - 1600-051X
pISSN - 0303-6979
DOI - 10.1111/jcpe.13255
Subject(s) - gingival recession , medicine , dentistry , major duodenal papilla , randomized controlled trial , clinical efficacy , surgery
Abstract Aim This study compared the clinical efficacy of the entire papilla preservation technique (EPP) alone and in combination with enamel matrix proteins plus bovine‐derived bone substitutes (EPP EMD + BS) in the treatment of isolated inter‐dental intrabony defects. Material and methods Thirty patients, each with one isolated intrabony defect, were randomly assigned to EPP EMD + BS or EPP alone. Clinical outcomes were assessed 1‐year post‐surgery. Results Early healing phase was uneventful in all cases, and 100% primary wound closure was maintained throughout the study period. Intragroup differences between baseline and 1‐year were statistically significant in both groups in terms of clinical attachment level (CAL) gain and probing depth (PD) reduction ( p ≤ .001). No statistically significant differences were detected in gingival recession (REC) ( p > .05). No statistically significant differences were detected in terms of CAL gain (6.3 ± 2.5 mm vs. 5.83 ± 1.12 mm), PD reduction (6.5 ± 2.65 mm vs. 6.2 ± 1.33 mm) or increase in gingival recession (0.2 ± 0.25 mm vs. 0.36 ± 0.54 mm) between the groups treated with EPP EMD + BS or EPP alone. Conclusions Application of EPP with and without regenerative biomaterials resulted in significant amounts of CAL gain and PD reduction, with negligible increase in gingival recession. Within the limits of the present study, it can be concluded that the addition of regenerative biomaterials does not improve the clinical outcomes of EPP alone. NCT03923465.